Literature DB >> 15149535

Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment.

F Vázquez-López, J A Manjón-Haces, R Pérez-Alvarez, N Pérez-Oliva.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149535     DOI: 10.1111/j.1365-2133.2004.05957.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

1.  Hepatitis C Virus Therapy-related Skin Manifestations.

Authors:  Brett E Fortune; Shayla Francis; Lisa M Forman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-05

2.  Onychomycosis Case Developing during Interferon Treatment.

Authors:  Nazan Tuna; Mustafa Teoman Erdem; Oğuz Karabay
Journal:  Balkan Med J       Date:  2013-03       Impact factor: 2.021

Review 3.  Eczematous Drug Eruptions.

Authors:  Amy E Blum; Susan Burgin
Journal:  Am J Clin Dermatol       Date:  2021-02-15       Impact factor: 7.403

Review 4.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

Review 5.  Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.

Authors:  Antonio Martinez-Lopez; Carlos Cuenca-Barrales; Trinidad Montero-Vilchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Am Acad Dermatol       Date:  2020-08-07       Impact factor: 11.527

6.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.